## Founding Date | 1986 |

Shire is a subsidiary of Takeda Pharmaceutical

Shire revenue breakdown by business segment: 26.2% from Hematology, 10.0% from Genetic Diseases, 18.4% from Neuroscience, 30.2% from Immunology, 11.6% from Internal Medicine and 3.6% from Other

GBP | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Revenue | 11.4b | 15.2b | 43.0m |

| 70% | 33% | |

## Operating expense total | 46.4m | 5.3b | |

## Depreciation and amortization | 1.2b | 1.8b | 9.0k |

## EBITDA | 1.8m | ||

| 0% | ||

## EBIT | 1.1m | 2.5b | |

| 0% | 16% | |

## Interest expense | 39.0k | ||

## Interest income | 2.2m | ||

## Pre tax profit | 2.4m | 6.3m | 3.8m |

## Income tax expense | (28.0k) | 3.2m | 376.0k |

## Net Income | 2.5m | 3.1m | 3.4m |

- Source: SEC Filings

- Source: SEC Filings

GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 45.7k | 219.3k | 17.0k | 4.0k | 550.6m | 620.0m | 1.5b | 2.2b | 3.0b | 135.5m | 528.8m | 472.4m | |||||||||||

## Accounts Receivable | 5.0k | 4.0k | 692.5m | 845.0m | 824.2m | 961.2m | 1.2b | 2.6b | 3.0b | ||||||||||||||

## Prepaid Expenses | 45.1m | 174.9m | 221.8m | 263.0m | 221.5m | 197.4m | 806.3m | 795.3m | |||||||||||||||

## Inventories | 260.0m | 340.1m | 436.9m | 455.3m | 544.8m | 635.4m | 3.6b | 3.3b | |||||||||||||||

## Current Assets | 6.1m | 7.4m | 22.4m | 16.0m | 21.0m | 41.2m | 21.4m | 5.9m | 7.4m | 72.4m | 51.1m | 75.3m | 116.7m | 143.6m | 1.9b | 2.2b | 3.2b | 4.3b | 5.2b | 2.3b | 7.5b | 7.6b | 18.8m |

## PP&E | 205.5k | 188.0k | 432.0k | 507.0k | 12.1m | 12.3m | 12.7m | 20.7m | 19.5m | 21.3m | 23.3m | 22.9m | 26.9m | 38.8m | 853.4m | 932.1m | 955.8m | 891.8m | 837.5m | 828.1m | 6.5b | 6.6b | |

## Goodwill | 402.5m | 592.6m | 644.5m | 624.6m | 2.5b | 4.1b | 17.9b | 19.8b | |||||||||||||||

## Total Assets | 6.4m | 7.6m | 22.8m | 16.5m | 33.1m | 53.5m | 34.1m | 26.6m | 26.9m | 273.3m | 158.9m | 151.2m | 170.4m | 182.9m | 5.4b | 6.4b | 7.3b | 8.3b | 13.6b | 16.6b | 67.0b | 67.8b | 190.3m |

## Accounts Payable | 398.1k | 533.1k | 486.0k | 1.0m | 2.0m | 594.0k | 673.0k | 88.0k | 1.3m | 1.9m | 730.0k | 356.0k | 2.9m | 295.0k | 1.2b | 1.4b | 1.5b | 1.7b | 1.9b | 2.1b | 4.3b | 4.2b | 612.0k |

## Short-term debt | 860.7m | 1.1b | 1.1b | 3.1b | 2.8b | 6.3m | |||||||||||||||||

## Current Liabilities | 1.5m | 4.6m | 15.9m | 10.3m | 27.1m | 59.2m | 49.6m | 57.2m | 67.9m | 81.1m | 32.1m | 14.4m | 15.7m | 18.3m | 1.3b | 2.5b | 1.6b | 1.8b | 3.0b | 3.7b | 7.7b | 7.9b | 8.7m |

## Long-term debt | 1.1b | 1.1b | 69.9m | 19.9b | |||||||||||||||||||

## Non-Current Liabilities | 227.5m | 226.7m | 227.2m | 3.6m | 6.6m | 30.3b | 28.0k | ||||||||||||||||

## Total Debt | 278.0k | 1.2m | 2.9m | 4.8m | 4.9m | 2.9m | 540.0k | 56.0k | 124.0k | 1.1b | 860.7m | 2.2b | 1.6b | 19.9b | 19.5b | 6.3m | |||||||

## Total Liabilities | 1.5m | 4.6m | 15.9m | 10.3m | 27.1m | 59.2m | 49.6m | 57.2m | 67.9m | 308.6m | 258.8m | 241.6m | 19.3m | 24.9m | 2.9b | 3.2b | 3.5b | 3.0b | 5.0b | 6.8b | 38.1b | 31.6b | 8.8m |

## Common Stock | 55.7m | 55.7m | 55.7m | 58.6m | 58.7m | 58.9m | 81.3m | 81.6m | 230.6m | ||||||||||||||

## Additional Paid-in Capital | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 230.6m | 230.6m | 2.7b | 2.9b | 3.0b | 4.2b | 4.3b | 4.5b | 24.7b | 25.1b | |

## Retained Earnings | (939.6k) | (1.9m) | 1.2m | (762.0k) | (179.0k) | (12.2m) | (9.8m) | (15.1m) | (10.5m) | 5.7m | (65.5m) | 7.5m | 15.1m | 4.7m | (160.3m) | 502.9m | 995.5m | 1.5b | 4.6b | 5.8b | 5.9b | 9.9b | (34.1m) |

## Total Equity | 4.9m | 3.0m | 6.9m | 6.2m | 6.0m | (5.7m) | (15.5m) | (30.5m) | (41.1m) | (35.3m) | (99.9m) | (90.4m) | 151.1m | 157.9m | 2.5b | 3.2b | 3.8b | 5.4b | 8.7b | 9.8b | 28.9b | 36.2b | 181.5m |

## Debt to Equity Ratio | 0.1 x | 0.2 x | 0.5 x | 0.8 x | -0.9 x | -0.2 x | 0 x | 0 x | 0 x | 0.4 x | 0.3 x | 0.6 x | 0.2 x | 0.7 x | 0.5 x | 0 x | |||||||

## Debt to Assets Ratio | 0 x | 0.1 x | 0.2 x | 0.1 x | 0.1 x | 0.1 x | 0 x | 0 x | 0 x | 0.2 x | 0.1 x | 0.3 x | 0.1 x | 0.3 x | 0.3 x | 0 x | |||||||

## Financial Leverage | 1.3 x | 2.5 x | 3.3 x | 2.7 x | 5.5 x | -9.4 x | -2.2 x | -0.9 x | -0.7 x | -7.7 x | -1.6 x | -1.7 x | 1.1 x | 1.2 x | 2.2 x | 2 x | 1.9 x | 1.6 x | 1.6 x | 1.7 x | 2.3 x | 1.9 x | 1 x |

- Source: SEC Filings

- Source: SEC Filings

- Source: SEC Filings

- Source: SEC Filings

FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | |
---|---|---|---|---|

## Phase I Trials Products | 7 | 6 | 6 | 7 |

## Phase II Trials Products | 11 | 6 | 10 | 10 |

## Phase III Trials Products | 7 | 14 | 17 | 15 |

## Approved Phase Products | 2 | 3 | 4 | 7 |

## Projects in R&D Pipeline | 27 | 29 | 37 | 40 |

## Countries | 68 | 72 | 100 | 100 |

## Preclinical Phase Products | 33 | 33 | 35 | 35 |

## Franchises | 7 | |||

## Manufacturing Sites | 14 | |||

## New Product Launches | 50 | |||

## Products Marketed | 40 |